In today’s briefing:
- Ohayo Japan | Wall Street Falls as New Tariffs Loom
- Japan Activist Briefs | Aichi Steel, Yodogawa Steel
- Japan Morning Connection: Trump Tariffs Set to Roil Markets to Start the Week
- CHMP Meeting Update: Eight New Medicines Recommended For Approval
Ohayo Japan | Wall Street Falls as New Tariffs Loom
- U.S. stocks declined Friday as the White House announced new tariffs on Mexico, Canada, and China taking effect Saturday
- Japanese markets ended mixed last week, with NEC leading gains, surging 18.4% on a stock split announcement and upward guidance revision. The broader TOPIX gained 1.4% for the week
- Companies reporting strong results included SCREEN Holdings, TDK, Fujitsu, MOL, Sakura Internet, and ZOZO
Japan Activist Briefs | Aichi Steel, Yodogawa Steel
- Investor activism and undervaluation are driving renewed interest in the steel sector, with Aichi and Yodogawa Steel facing pressure to unlock shareholder value.
- Asset Value increased their stake in Sharing Tech. It ticks a lot of boxes: strong growth, high profitability, robust cash reserves, & shareholder-friendly policies.
- Nippon Active Value increased its stake in ASKA Pharma due to its strong fundamentals, undervaluation, profitability, and potential for shareholder value enhancement through cross-shareholding reductions.
Japan Morning Connection: Trump Tariffs Set to Roil Markets to Start the Week
- Jensen in the White House did little to help NVDA on the spectre of further restrictions.
- NEC +18% in one of its biggest moves ever on Friday as defense takes a bigger role.
- Screen and Lasertec both reported earnings beats but its a mixed bag for both under the hood.
CHMP Meeting Update: Eight New Medicines Recommended For Approval
- In its January 2025 meeting, EMA’s human medicines committee (CHMP) recommended eight medicines for approval, including four innovative, three biosimilars, and one generic drugs.
- The committee has also recommended extensions of indication for eight medicines that are already authorized in the EU.
- Marketing applications for two medicines were withdrawn. Among them, withdrawal of Daiichi Sankyo’s datopotamab deruxtecan for non-squamous non-small cell lung cancer is noteworthy.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
